Fucosidosis Therapeutics MarketThe global Fucosidosis Therapeutics Market is projected to grow significantly, reaching a market value of USD 17.91 Million by 2033, up from USD 10 Million in 2023, ...

JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; "JCR") announced today that the Company presented preclinical data from its novel adeno-associated virus (AAV) gene ...

The Association des optométristes du Québec (AOQ) regretfully announces that 85% of its members have decided to withdraw from ...

(Alliance News) - Syncona Ltd on Wednesday noted positive trial results for a portfolio company's gene therapy aimed at treating people with Gaucher's disease.

MeiraGTx (MGTX) announced the Company will exhibit five posters at the European Society of Gene and Cell Therapy, ESGCT, 2024 Annual Congress, ...

Gov. Kathy Hochul on Tuesday announced a $150 million investment in the new state-of-the-art therapy hub to be built on ...

Gov. Kathy Hochul on Tuesday announced a $150 million investment in a new state-of-the-art cell and gene therapy hub to be built on Long Island.

A 12-year-old boy has become the first patient in the U.S. to receive gene therapy for sickle cell disease, The New York Times reported Oct ...

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for its clinical-stage treatment reni-cel.

Editas Medicine is ousting its ex vivo sickle cell and beta thalassemia gene therapy to instead focus on an in vivo treatment ...

The posters are available on the Posters and Publications page of the Company’s website.

Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces upcoming oral and poster ...